Carotid Body Cancer

Categories: Cancer diseases, Cardiovascular diseases

Aliases & Classifications for Carotid Body Cancer

MalaCards integrated aliases for Carotid Body Cancer:

Name: Carotid Body Cancer 12
Malignant Carotid Body Paraganglioma 12
Malignant Neoplasm of Carotid Body 69
Malignant Carotid Body Tumor 12
Cancer of Carotid Body 12


External Ids:

Disease Ontology 12 DOID:8731
ICD10 33 C75.4
ICD9CM 35 194.5
NCIt 47 C3574
UMLS 69 C0153656

Summaries for Carotid Body Cancer

Disease Ontology : 12 A vascular cancer that is characterized by an encapsulated, firm round mass at the bifurcation of the common carotid artery.

MalaCards based summary : Carotid Body Cancer, is also known as malignant carotid body paraganglioma. The drugs Ethanol and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and spinal cord.

Related Diseases for Carotid Body Cancer

Symptoms & Phenotypes for Carotid Body Cancer

Drugs & Therapeutics for Carotid Body Cancer

Drugs for Carotid Body Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Ethanol Approved Phase 4 64-17-5 702
2 Hormone Antagonists Phase 4,Phase 2,Phase 1
3 Hormones Phase 4,Phase 2,Phase 1
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
5 insulin Phase 4
6 Insulin, Globin Zinc Phase 4
7 Antimetabolites Phase 4,Phase 2
8 Anticholesteremic Agents Phase 4
9 Calcium, Dietary Phase 4
10 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
11 Hypolipidemic Agents Phase 4
12 Lipid Regulating Agents Phase 4
13 Rosuvastatin Calcium Phase 4 147098-20-2
Doxazosin Approved Phase 3 74191-85-8 3157
Phenoxybenzamine Approved Phase 3 59-96-1 4768
16 3-Iodobenzylguanidine Phase 3,Phase 2,Phase 1
17 Radiopharmaceuticals Phase 3,Phase 2,Phase 1
18 Adrenergic Agents Phase 3
19 Adrenergic alpha-1 Receptor Antagonists Phase 3
20 Adrenergic alpha-Antagonists Phase 3
21 Adrenergic Antagonists Phase 3
22 Antihypertensive Agents Phase 3
23 Neurotransmitter Agents Phase 3
24 Vasodilator Agents Phase 3
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
29 Racepinephrine Approved Phase 2
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
Somatostatin Approved Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
Lenvatinib Approved Phase 2 417716-92-8
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
nivolumab Approved Phase 2 946414-94-4
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
Iodine Investigational Phase 1, Phase 2 7553-56-2 807
38 Angiogenesis Inhibitors Phase 2
39 Angiogenesis Modulating Agents Phase 2
40 cadexomer iodine Phase 1, Phase 2
41 Anti-Bacterial Agents Phase 2,Phase 1
42 Antibiotics, Antitubercular Phase 2,Phase 1
43 Antifungal Agents Phase 2,Phase 1
44 Anti-Infective Agents Phase 2,Phase 1
45 Epinephryl borate Phase 2
46 Immunosuppressive Agents Phase 2,Phase 1
47 Antineoplastic Agents, Hormonal Phase 2,Phase 1
48 Gastrointestinal Agents Phase 2,Phase 1
49 Antibodies Phase 2,Phase 1
50 Antibodies, Monoclonal Phase 2,Phase 1

Interventional clinical trials:

(show all 41)

id Name Status NCT ID Phase Drugs
1 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
2 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
3 Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging Enrolling by invitation NCT02114697 Phase 4 Rosuvastatin
4 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
5 Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
6 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
7 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed NCT00843037 Phase 2 Sunitinib
8 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors Completed NCT01560260 Phase 2 Linsitinib
9 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
10 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2 RAD001
11 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;Amino Acid
12 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Recruiting NCT03008369 Phase 2 Lenvatinib
13 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
14 A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Recruiting NCT03165721 Phase 2 SGI-110 (guadecitabine)
15 Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies Recruiting NCT02177773 Phase 2 DOTA-TOC PET/CT
16 Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib
17 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2 PEN-221
18 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
19 Dovitinib in Neuroendocrine Tumors Active, not recruiting NCT01635907 Phase 2 Dovitinib
20 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
21 A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
22 Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
23 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
24 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
25 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
26 ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
27 Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1 Vandetanib
28 Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers Completed NCT00188019
29 Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma Completed NCT01022515
30 Familial Investigations of Childhood Cancer Predisposition Recruiting NCT03050268
31 Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions Recruiting NCT03160274
32 Bioimpedance, Arterial Stiffness and Hemodynamic Instability During Induction of General Anesthesia Recruiting NCT03237429
33 Stereotactic Body Radiotherapy for Spine Tumors Active, not recruiting NCT01347307
34 Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Active, not recruiting NCT02186678
35 Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Available NCT02961491 Ultratrace Iobenguane I131
36 Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma Available NCT01838187
37 18F-FDOPA PET in Neuroendocrine Tumours Available NCT02431715 [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
38 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma Available NCT01163383 131 I-Metaiodobenzylguanidine (131 I-MIBG);131 I-MIBG
39 Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma Available NCT01377532 131 I-Metaiodobenzylguanidine (131 I-MIBG)
40 Expanded Access Protocol Using I131-MIBG Available NCT01590680
41 Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma Terminated NCT00911729

Search NIH Clinical Center for Carotid Body Cancer

Genetic Tests for Carotid Body Cancer

Anatomical Context for Carotid Body Cancer

MalaCards organs/tissues related to Carotid Body Cancer:

Lung, Kidney, Spinal Cord, Brain

Publications for Carotid Body Cancer

Variations for Carotid Body Cancer

Expression for Carotid Body Cancer

Search GEO for disease gene expression data for Carotid Body Cancer.

Pathways for Carotid Body Cancer

GO Terms for Carotid Body Cancer

Sources for Carotid Body Cancer

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....